Company: WW
Filing Date: 2025-04-21
Form Type: DEF 14A
Source: 0001193125-25-087213
Chunk: 26

Company: WW INTERNATIONAL, INC.
Filing Date: 2025-04-21
Form: DEF 14A
Chunk 26
---
 Exhibit 19.1 to our Annual Report on Form 10-Kfor the year ended December 28, 2024. Executive Sessions of Non-Managementand Independent Directors Non-managementdirectors meet in executive sessions of the Board of Directors in which management directors and other members of management do not participate. These sessions are periodically scheduled for non-managementdirectors at meetings of the Board of Directors. The Chairman of the Board of Directors, currently Mr. Semmelbauer, presides over the meetings of the non-managementdirectors. In addition, the directors who the Board of Directors affirmatively determined are independent under applicable Nasdaq listing standards and our Corporate Governance Guidelines hold executive sessions at least twice a year. Mr. Kelly presided over these sessions in fiscal 2024. 18

#### INFORMATION ABOUT OUR EXECUTIVE OFFICERS AND DIRECTORSSet forth below are the names, ages, and current positions with us as of April 21, 2025 of our executive officers and directors. Directors are elected at the annual meeting of shareholders. Executive officers are appointed by, and hold office at, the discretion of the Board of Directors.NameAgePositionTara Comonte51President and Chief Executive Officer, DirectorFelicia DellaFortuna41Chief Financial OfficerMichael Amsel41Chief Marketing OfficerJacqueline Cooke46Chief Legal and Administrative Officer and SecretaryThilo Semmelbauer(1)(2)59Chairman of the Board of DirectorsSteven M. Altschuler, M.D.(3)71DirectorJulie Bornstein(3)55DirectorTracey D. Brown(1)(2)57DirectorDenis F. Kelly(2)75DirectorWilliam H. Shrank, M.D.53Director(1)Member of the NCG Committee.(2)Member of the Audit Committee.(3)Member of the Compensation Committee.Tara Comonte. Ms. Comonte has served as our President and Chief Executive Officer since February 2025 and has been a director since June 2023. She previously served as our Interim President and Chief Executive Officer from September 2024 to February 2025. With over two decades of executive leadership experience across corporate and digital strategy, technology, operations and finance, Ms. Comonte has navigated a broad range of industries and complex business transitions. She served as Chief Executive Officer of TMRW Life Sciences, Inc., a life sciences technology company focused on the in vitro fertilization (IVF) sector, from May 2021 to July